Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reginator (also known as EAAlpha) is a patented, vegan-friendly amino acid formulation consisting of nine essential amino acids plus arginine. Developed over 20 years at the University of Arkansas for Medical Sciences, it is designed to stimulate muscle protein synthesis and increase serum insulin-like growth factor 1 (IGF-1) levels. The supplement is positioned as a highly efficient anabolic activator, with clinical data suggesting that low doses can outperform significantly larger quantities of whey protein in promoting muscle health and cellular recovery. It is primarily targeted at adults experiencing age-related declines in growth hormone and IGF-1, and has been evaluated in numerous human clinical trials for its efficacy in supporting muscle mass and metabolic health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Reginator.